Evidence map›Paper›PMID 35039676›Full record

ReviewNature reviews. Drug discovery2022

Immune targets for therapeutic development in depression: towards precision medicine.

Wayne C Drevets, Gayle M Wittenberg, Edward T Bullmore, Husseini K Manji

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Drug discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 190 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
190citing papers in PubMed, 9 pooled it
19.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

190 citing papers in PubMed, 9 syntheses or guidelines pooled it, 315 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

130 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Wayne C Drevets *Neuroscience, Janssen Research & Development, LLC, San Diego, CA, USA.
Gayle M Wittenberg *Data Science, Janssen Research & Development, LLC, Titusville, NJ, USA.
Edward T BullmoreDepartment of Psychiatry, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-8955-8283
Husseini K ManjiScience for Minds, Johnson & Johnson, New Brunswick, NJ, USA. hmanji@its.jnj.com.
Janssen (United States) · USJohnson & Johnson (United States) · USUniversity of Cambridge · GB

Funding

Medical Research Council MC_G0802534Medical Research Council MR/L014815/1Wellcome Trust
6 · The paper itself

Abstract

Over the past two decades, compelling evidence has emerged indicating that immune mechanisms can contribute to the pathogenesis of major depressive disorder (MDD) and that drugs with primary immune targets can improve depressive symptoms. Patients with MDD are heterogeneous with respect to symptoms, treatment responses and biological correlates. Defining a narrower patient group based on biology could increase the treatment response rates in certain subgroups: a major advance in clinical psychiatry. For example, patients with MDD and elevated pro-inflammatory biomarkers are less likely to respond to conventional antidepressant drugs, but novel immune-based therapeutics could potentially address their unmet clinical needs. This article outlines a framework for developing drugs targeting a novel patient subtype within MDD and reviews the current state of neuroimmune drug development for mood disorders. We discuss evidence for a causal role of immune mechanisms in the pathogenesis of depression, together with targets under investigation in randomized controlled trials, biomarker evidence elucidating the link to neural mechanisms, biological and phenotypic patient selection strategies, and the unmet clinical need among patients with MDD.

Indexed as

Major Depressive DisorderAntidepressive AgentsBiomarkersDepressionHumansPrecision MedicineAntidepressive AgentsBiomarkers

Identifiers

PMID35039676
PMCPMC8763135
OpenAlexW4206213217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.